abiraterone,olaparib
astrazeneca,merck
['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'propel']
final pre-specificied os in propel study by prof noel clark: no significant benefit in itt population but nice results in hrrm #gu23 
Medical oncologist. Clinical researcher focused in GU tumors. Associate Professor UCM. Hospital Clinico San Carlos Madrid, Spain